NASDAQ: SCNIScinai Immunotherapeutics Ltd Stock
$0.47-0.01 (-2.08%)
Updated Apr 24, 2024
SCNI Price
$0.47
Fair Value Price
N/A
Market Cap
$2.06M
52 Week Low
$0.43
52 Week High
$2.27
P/E
-0.1x
P/B
-0.76x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$10.95M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-7.9
Operating Cash Flow
N/A
Beta
0.92
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
SCNI Overview
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SCNI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SCNI is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SCNI is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
SCNI's short-term assets ($6.71M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
There are 30 more SCNI due diligence checks available for Premium users.
Be the first to know about important SCNI news, forecast changes, insider trades & much more!
SCNI News
Valuation
SCNI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.1x
Industry
15.69x
Market
41.27x
SCNI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.76x
Industry
5.86x
SCNI's financial health
Profit margin
Revenue
$0.0
Net Income
-$3.1M
Profit Margin
0%
Assets to liabilities
Assets
$18.6M
Liabilities
$21.3M
Debt to equity
-7.9
SCNI's short-term assets ($6.71M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SCNI's long-term liabilities ($19.74M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SCNI's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SCNI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.2M
Investing
-$20.0k
Financing
$1.1M
SCNI vs Biotech Stocks
Scinai Immunotherapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.